Role of vascular endothelial growth factor on erythropoietin-related endothelial cell proliferation

• Published in: Journal of the American Society of Nephrology 1998-11, Vol.9 (11), p.1998-2004
• Main Authors: ALVAREZ ARROYO, M. V, ANGELES CASTILLA, M, GONZALEZ PACHECO, F. R, DUNYONG TAN, RIESCO, A, CASADO, S, CARAMELO, C
• Format: Article
• Language: English
• Subjects: Animals; Aorta - cytology; Aorta - drug effects; Aorta - physiology; Biological and medical sciences; Cardiovascular system; Cattle; Cell Division - drug effects; Cell Division - physiology; Endothelial Growth Factors - physiology; Endothelium, Vascular - cytology; Endothelium, Vascular - drug effects; Endothelium, Vascular - physiology; Enzyme Inhibitors - pharmacology; Erythropoietin - pharmacology; Genistein - pharmacology; Humans; Investigative techniques, diagnostic techniques (general aspects); Lymphokines - physiology; Medical sciences; Pathology. Cytology. Biochemistry. Spectrometry. Miscellaneous investigative techniques; Protein-Tyrosine Kinases - antagonists & inhibitors; Proto-Oncogene Proteins - genetics; Receptor Protein-Tyrosine Kinases - genetics; Receptors, Growth Factor - genetics; Receptors, Vascular Endothelial Growth Factor; Recombinant Proteins; RNA, Messenger - metabolism; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factors
• ISSN: 1046-6673; 1533-3450
• DOI: 10.1681/ASN.V9111998

The vascular actions of recombinant human erythropoietin (rhEPO) are of particular relevance for fully understanding rhEPO effects. This study examines the mechanisms of action of rhEPO on endothelial cells from bovine aorta (BAEC). First, the studies demonstrated that rhEPO acts on BAEC proliferation as a comitogenic growth factor in the presence of fetal calf serum (FCS). The main experimental findings disclosed that an interaction between rhEPO and vascular endothelial growth factor (VEGF) is instrumental for the growth-promoting action of rhEPO, as shown by the blockade (92.8+/-2.2% inhibition, P < 0.01) of the rhEPO-induced BAEC proliferation by a specific anti-VEGF antibody and by the capability of VEGF for substituting FCS in the induction of rhEPO-related BAEC proliferation (increase in BAEC number in the absence of FCS: 20 U/ml rhEPO alone, 0.3+/-2.8%; 5 x 10(-11) M VEGF alone, 52.9+/-3.1%; 20 U/ml rhEPO + 5 X 10(-11) M VEGF, 117.8+/-6.9%, P < 0.01 between the two agents combined with respect to each agent alone). The existence of a positive interaction between rhEPO and VEGF was further demonstrated by observing an increased cytosolic Ca2+ ([Ca2+]i) mobilization response to VEGF (10(-11)M) in BAEC pretreated or not with 20 U/ml rhEPO (delta[Ca2+]i = 704+/-111 versus 246+/-36 nM, respectively, P < 0.01). To further examine the mechanism of the potentiation of VEGF effect by rhEPO, we analyzed the mRNA expression of the VEGF receptors KDR/flk-1 and flt-1. The results disclosed that BAEC pretreatment with rhEPO upregulated the expression of both KDR/flk-1 and flt-1, therefore providing a structural basis for the aforementioned positive interactions between VEGF and rhEPO. Furthermore, inhibition by genistein suggests that tyrosine phosphorylation was involved in the VEGF receptor upregulation. The mechanisms identified in the present study disclose an interaction at the level of mRNA expression and functional effects between a hormone with predominantly hemopoietic effects, namely, erythropoietin, and an angiogenic factor, namely, VEGF. This relationship between rhEPO and VEGF might be of particular importance in neovascularization processes and in patients receiving rhEPO as a treatment.